Table 6.
Antigen-Specific Approach | Delivery Strategy | Disease Model | Ref(s) | |
---|---|---|---|---|
Antigen | ||||
PLP | PLGA MPs | Multiple sclerosis | [240,241] | |
Collagen scaffold | Multiple sclerosis | [112] | ||
Ins29–23 | PLGA MPs | Inflammatory diabetes | [245] | |
Antigen and small molecules/biologics | ||||
MOG | Rapamycin | PLGA MPs | Multiple sclerosis | [43] |
Dexamethasone | Acetalated dextran MPs | Multiple sclerosis | [246] | |
Vitamin D3, TGF-β1, GM-CSF | PLGA MPs | Multiple sclerosis | [185] | |
Insulin B | Vitamin D3, TGF-β1, GM-CSF | PLGA MPs | Inflammatory diabetes | [187] |
Denatured insulin | Vitamin D3, TGF-β1, GM-CSF | PLGA MPs | Inflammatory diabetes | [188] |
Collagen II | Vitamin D3, TGF-β1, GM-CSF | PLGA MPs | Inflammatory arthritis | [248] |
PFK15 inhibitor | Poly-aKG MPs | Inflammatory arthritis | [152] |